We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > asciminib

News List

Access to Novartis treatment for Myeloid leukaemia patients pharmatimes
January 25, 2022
Novartis UK has announced that the MHRA has given a positive scientific opinion for the investigational treatment, asciminib
USFDA awards Breakthrough Therapy designation to Novartis’ asciminib pharmaceutical-business-review
February 10, 2021
Novartis has announced that the novel investigational treatment asciminib, specifically targeting the ABL myristoyl pocket (STAMP), has been awarded Breakthrough Therapy designation (BTD) by the US Food and Drug Administration (FDA).
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study pharmaceutical-business-review
September 01, 2020
Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib (ABL001) vs. bosutinib.
Novartis' CML drug hits PhIII targets pharmatimes
August 26, 2020
Novartis' Phase III ASCEMBL study has met its primary goal showing that asciminib was superior to bosutinib in inducing a major molecular response (MMR) in patients with a certain from of chronic myeloid leukaemia (CML).